AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 121 min read$ABSI

HC Wainwright & Co. reiterates Buy rating on Absci, $16 price target

HC Wainwright & Co. maintained a Buy rating on Absci (ABSI) with a $16 price target, suggesting a 57.5% upside from the Oct 9 close. The firm highlighted the potential of ABS-201, Absci's lead product candidate, and positive preliminary data on its effects on stem cells.

Original reporting
tradingview.com
Published Oct 12, 2026, 11:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 11:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Absci, $16 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$ABSIBullishLow
01

Why it matters

The rating upgrade could lead to modest buying pressure on Absci.

02

Market read

Analyst upgrade with a high price target may influence short-term trading in ABSI.

03

What to watch

No new clinical data released; rating is based on expectations.

Relevance 6/10Novelty 5/10Timing: today

Background

HC Wainwright provides equity research coverage on biotech companies.

Company-level read

Ticker impact

$ABSIBullishMedium confidence
Context

HC Wainwright reiterated a Buy rating on Absci and set a new $16 price target, implying a 57.5% upside.

Expected impact

potential upward pressure as investors price in the new target

Evidence & confidence

Buy rating and sizable upside target can drive short-term demand.

Market effects

Sector

May boost sentiment in the biotech sector as analysts raise targets.

Regional

Limited to US-listed biotech investors.

Global

Minimal global impact beyond Absci.

Counterpoint

What could challenge this read

The target may be overly optimistic given early-stage data.

Key entities

  • Research Firm
    HC Wainwright & Co.

    Equity research analyst firm issuing the rating.

  • Company
    Absci

    Biotech firm developing antibody ABS-201.

Read at source← All news

Related articles

SEP 24
$ABSILow

Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis

Absci Corporation (ABSI) announced plans for a Phase 2 trial of ABS-201, an AI-designed antibody for endometriosis, expected to start in mid-2027. The trial will assess efficacy and safety in 150 patients across 10 countries, focusing on pain reduction. ABS-201 targets the prolactin receptor, offering a non-hormonal approach to treatment.

finanznachrichten.de2 min
AUG 19
$ABSIMed

Absci (ABSI) Q2 2026 Earnings Call Transcript

Absci (ABSI) reported Q2 2026 revenue of $0.3M, down from $0.6M in 2025, with a net loss of $33.2M. R&D expenses rose to $22.6M, driven by ABS-201 clinical progress. Cash increased to $201.1M, supported by a $100M financing round, including $40M from Eli Lilly. The company expects ABS-201 data in late 2026 and 2027, with Phase II endometriosis trials starting in Q4 2026. Management highlighted a 2028 cash runway and platform advancements.

fool.com3 min
AUG 11
$ABSIHighAI 9/10

Why is Absci stock tumbling today?

Absci Corp shares fell 16.6% in after-hours after reporting Q2 2026 results. According to the company, revenue was $0.3M versus about $1.01M expected and down from $0.6M a year earlier. The per-share loss was $0.21 versus a $0.19 expected loss, with a $33.2M net loss. CEO cited Phase 1 HEADLINE trial interim data, but investors focused on the financial miss.

investing.com3 min
AUG 11
$ABSIMed

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corp (ABSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly

SEC EDGAR 8-K6 min
JUN 26
$ABSIMed

Absci (NASDAQ:ABSI) Shares Gap Up Following Analyst Upgrade

Absci Corp. (NASDAQ:ABSI) shares rose premarket Wednesday after HC Wainwright upgraded its outlook, raising the price target from $8.00 to $16.00 and keeping a buy rating. The stock closed at $7.41 and opened at $9.51. Other analysts set targets from $11 to $15. The move follows positive interim Phase 1 ABS-201 data and a $100 million underwritten offering.

themarketsdaily.com3 min